

USSN - 09/845,717

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (original). Method for treatment or prevention of a non-ischemic condition in one or more organ(s) or tissue(s), the method comprising administering of an effective dosage of  $\alpha$ -MSH and/or of an  $\alpha$ -MSH equivalent and/or a dosage of EPO and/or an EPO equivalent to the individual in need thereof.

2 (original). Method according to claim 1 wherein the dosage of  $\alpha$ -MSH and/or of an  $\alpha$ -MSH equivalent and/or EPO and/or an EPO equivalent is administered prophylactically for preventing the establishment or progress of the condition, or of any symptom of the condition.

3 (original). Method for treatment or prevention of an inflammatory condition in one or more organ(s) or tissue(s), the method comprising administering of an effective dosage of  $\alpha$ -MSH and/or of an  $\alpha$ -MSH equivalent and/or a dosage of EPO and/or an EPO equivalent to the individual in need thereof.

4 (original). Method according to claim 3 wherein the dosage of  $\alpha$ -MSH and/or of an  $\alpha$ -MSH equivalent and/or EPO and/or an EPO equivalent is administered prophylactically for preventing the establishment or progress of the condition, or of any symptom of the condition.

5 (previously presented). Method according to claim 1 wherein the dosage of  $\alpha$ -MSH and/or of an  $\alpha$ -MSH equivalent and EPO and/or an EPO equivalent is administered as a single dosage, regular or continued administration, or as a sequential administration.

6 (previously presented). Method according to claim 1 wherein condition is caused by an infection.

USSN - 09/845,717

7 (previously presented). Method according to claim 1 wherein the condition is caused by a cancer or a by premalignant disorder.

8 (previously presented). Method according to claim 1 wherein the  $\alpha$ -MSH equivalent is a substance acting on the  $\alpha$ -MSH receptor and/or on the melanocortin receptor.

9 (previously presented). Method according to claim 1 wherein the treatment or prevention comprises administration of a dosage unit of EPO and/or an EPO equivalent.

10 (currently amended). Method according to claim 1 wherein a combination of  $\alpha$ -MSH and/or  $\alpha$ -MSH equivalent with EPO and/or an EPO equivalent is ~~administered~~ administered.

11 (cancelled).

12 (original). A pharmaceutical composition comprising a unit dosage of EPO and/or EPO equivalent and a unit dosage of  $\alpha$ -MSH and/or of an  $\alpha$ -MSH equivalent together with a suitable pharmaceutical carrier.

13 (previously presented). Method according to claim 3 wherein the dosage of  $\alpha$ -MSH and/or of an  $\alpha$ -MSH equivalent and EPO and/or an EPO equivalent is administered as a single dosage, regular or continued administration, or as a sequential administration.

14 (previously presented). Method according to claim 3 wherein condition is caused by an infection.

15 (currently amended). Method according to claim 3 wherein the condition is caused by a cancer or ~~a~~ by a premalignant disorder.

16 (previously presented). Method according to claim 3 wherein the  $\alpha$ -MSH equivalent is a substance acting on the  $\alpha$ -MSH receptor and/or on the melanocortin receptor.

17 (previously presented). Method according to claim 3 wherein the treatment or prevention comprises administration of

USSN - 09/845,717

a dosage unit of EPO and/or an EPO equivalent.

18 (currently amended). Method according to claim 3 wherein a combination of  $\alpha$ -MSH and/or  $\alpha$ -MSH equivalent with EPO and/or an EPO equivalent is ~~administered~~ administered.

19 (new). The method of claim 1 where said condition is characterized by inflammation of the lung or airways.

20 (new). The method of claim 19 where said condition is chronic obstructive pulmonary disease (COPD).

21 (new). The method of claim 1 where said condition is characterized by inflammation of the kidney or the urinary tract.

22 (new). The method of claim 1 where said condition is not caused by cancer or infection.

23 (new). The method of claim 1 in which the condition is caused by a chemical trauma, or a physical obstruction, trauma or injury.

24 (new). The method of claim 1 in which the condition is caused by an allergic reaction.